DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "OpportunityAnalyzer: Hepatocellular Carcinoma - Opportunity Analysis and Forecasts to 2024" report to their offering.
Hepatocellular carcinoma (HCC) is the most dominant form of liver cancer, accounting for approximately 85% of liver cancer cases. The prognosis of HCC is dependent on the stage of the disease at diagnosis. However, even with treatments such as surgical resection, liver transplantation, and ablative therapies, which are only suitable for early-stage HCC patients, the majority of patients are likely to progress onto the advanced stages of the disease.
Key Questions Answered
- Nexavar, approved in 2007, is the only available targeted treatment option for patients with advanced HCC and has dominated the HCC market in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan) since its launch.
- The current late and early stage pipeline is very strong and diverse. Which drug will have the biggest impact on the market? What strategies are developers undertaking to overcome the high risk of clinical trial failure?
- Nexavar will lose patent protection within the forecast period. How will this impact the HCC market and will new market entries be able to stabilize the HCC market?
- The main driver of growth in the HCC market is the expected launch of second-line treatments for patients with advanced HCC. The market growth will be further supported by an increase in HCC incidence numbers due to a growing aging population as well as market-specific increase in risk factors.
- The biggest barrier for HCC is the patent expiry of Nexavar and expected introduction of generic sorafenib in the 7MM. The effect of this will be strongest in the US where it will have the largest impact on the HCC market. Further patent expiries will also have a negative impact on the HCC market.
- The largest unmet needs in HCC are more treatment options for patients with advanced HCC. First line as well as second line and beyond treatments are urgently needed to improve the treatability of these patients.
- Daiichi Sankyo
- Eli Lilly
- Kowa Company
- Kyowa Hakko Kirin
- Onxeo SA
- Polaris Pharmaceuticals
For more information visit http://www.researchandmarkets.com/research/vsfqt8/opportunityanalyze